Quality of Life Research

, Volume 21, Issue 7, pp 1255–1266

The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy

  • Leah Kleinman
  • Katy Benjamin
  • Hema Viswanathan
  • Maria Stoeckl Mattera
  • Linda Bosserman
  • Douglas W. Blayney
  • Dennis A. Revicki
Article

DOI: 10.1007/s11136-011-0034-1

Cite this article as:
Kleinman, L., Benjamin, K., Viswanathan, H. et al. Qual Life Res (2012) 21: 1255. doi:10.1007/s11136-011-0034-1

Abstract

Purpose

To develop a patient-reported outcome instrument for measuring anemia symptoms and their impact in patients with chemotherapy-induced anemia (CIA).

Methods

Qualitative research was conducted using six focus groups and 24 interviews with 46 CIA patients, eight interviews in patients receiving chemotherapy with no CIA history and two interviews in patients successfully treated for CIA. Atlas.ti 5.0 was used to organize key concepts. Cognitive interviews with 16 CIA patients and assessment of relevance of each item to CIA by 10 clinicians were also conducted to evaluate content validity.

Results

Most CIA patients were white (76%) and female (83%), and the average age was 60 years. The most common cancer types were breast cancer (54%) and lung cancer (17%). Tiredness was the most prevalent symptom and rated as the most important by 83% of CIA patients; weakness, shortness of breath, lightheadedness, and dizziness were ranked next in importance. The final anemia impact measure (AIM) contains: (1) daily CIA symptom diary (9 items), and (2) impact of CIA-related tiredness (29 items covering daily living activities, social activities, cognitive function, and emotions). Cognitive interviews found that the AIM was relevant and easy to understand.

Conclusions

The AIM assesses important patient-perceived CIA symptoms and their impact and was developed using extensive patient qualitative data.

Keywords

ChemotherapyAnemiaSymptomInstrument developmentContent validityQualitative research

Abbreviations

ADLs

Activities of Daily Living

AIM

Anemia Impact Measure

CIA

Chemotherapy-Induced Anemia

ePDA

Electronic Personal Digital Assistant

FACT-An

Functional Assessment of Cancer Therapy-Anemia

FACT-Fatigue

Functional Assessment of Cancer Therapy-Fatigue

FDA

Food and Drug Administration

Hb

Hemoglobin

HRQOL

Health-Related Quality of Life

IADLs

Instrumental Activities of Daily Life

MCS

Mental Component Summary Score

NIH

National Institutes of Health

PCS

Physical Component Summary Score

PDA

Personal Digital Assistant

PRO

Patient-Reported Outcomes

SD

Standard Deviation

Supplementary material

11136_2011_34_MOESM1_ESM.doc (106 kb)
Supplementary material 1 (DOC 106 kb)

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Leah Kleinman
    • 1
  • Katy Benjamin
    • 1
  • Hema Viswanathan
    • 2
  • Maria Stoeckl Mattera
    • 1
  • Linda Bosserman
    • 3
  • Douglas W. Blayney
    • 4
  • Dennis A. Revicki
    • 1
  1. 1.Outcomes Research, United BioSource CorporationUnited BioSource CorporationBethesdaUSA
  2. 2.Amgen, Inc.Thousand OaksUSA
  3. 3.Wilshire Oncology Medical GroupRancho CucamongaUSA
  4. 4.Stanford Cancer CenterStanfordUSA